Loading
A phase 3 trial of Tamoxifen, Triptorelin, Letrozole and Zoledronic acid in Breast cancer, run by National Cancer Institute, Naples, with a status the registry has not verified recently.
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer is a phase 3 interventional study registered as NCT00412022 by National Cancer Institute, Naples, with 1294 participants planned, started 2004-03 and due to reach its primary completion in 2024-11. Interventions recorded: tamoxifen, triptorelin, letrozole, zoledronic acid. Conditions recorded: Breast Cancer.
Linked to the drug Triptorelin because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Triptorelin, Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Zoledronic acid, Breast cancer (all types) and the tag pipeline.
Shares Triptorelin and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Triptorelin and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Zoledronic acid and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/